GORE VIABAHN Endoprosthesis and GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
W. L. Gore & Associates, Inc. · Decision date Oct 17, 2025
What did the FDA decide?
FDA records P130006/S110 as a supplement to PMA P130006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 17, 2025.
FDA approval order statement
implementation of an additional supplier of a raw material of the CBAS Heparin Surface
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 17, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P130006/S110
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- PFV
- Decision code
- OK30
- Decision date
- Oct 17, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- PFV
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130006/S110 received
Application receipt date recorded by FDA.
P130006/S110 · FDA decision
30-Day Notice
P130006/S111 · Related supplement
GORE VIABAHN Endoprosthesis, GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
Timeline entries are records held by MedtechLedger for P130006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA supplement | May 26, 2026 | FDA |
Explore the linked device profile
Other records with product code PFV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Fluency Plus Endovascular Stent GraftP130029/S015 | Bard Peripheral Vascular, Inc. | PMA supplement | Jun 22, 2026 | FDA |
WRAPSODY Cell-Impermeable EndoprosthesisP240023/S005 | Merit Medical Systems, Inc. | PMA supplement | Jun 11, 2026 | FDA |
Bard Fluency Plus Endovascular Stent GraftP130029/S014 | Bard Peripheral Vascular, Inc. | PMA supplement | Jun 10, 2026 | FDA |
Covera Vascular Covered StentP170042/S015 | C.R. Bard, Inc. | PMA supplement | Jun 10, 2026 | FDA |
Covera Vascular Covered StentP170042/S014 | C.R. Bard, Inc. | PMA supplement | Dec 16, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3250 W. Kiltie Ln., Flagstaff, AZ, 86001
Sources and methodology
- Original FDA record: P130006/S110
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



